Millennium's Vision Thing
Millennium's purchase of Leukosite appears to be a significant step towards its oft-stated goal of building a fully integrated pharmaceutical company. But some of the company's investors reacted less enthusiastically as stock prices tumbled immediately after the deal. Since then, the company's share price has almost returned to pre-deal levels. And Millennium's management says that it will reap tremendous benefits as the result of acquiring Leukosite's pipeline and late-stage clinical development capabilities,
You may also be interested in...
The Scientific Committee on Consumer Safety will consider available safety data for prostaglandin analogs isopropyl cloprostenate, ethyl tafluprostamide and others with known use in eyelash-growth cosmetic products in the EU. Currently, the substances are not restricted in cosmetic products.
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.